<DOC>
	<DOC>NCT01141959</DOC>
	<brief_summary>The investigators are interested in identifying patient-specific factors related to donor chimerism in patients who receive nonmyeloablative hematopoietic stem cell transplants from haploidentical donors. We will look how patients' bodies break down and immediately respond to cyclophosphamide, fludarabine and mycophenolate mofetil.</brief_summary>
	<brief_title>Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Scheduled to receive nonmyeloablative conditioning which includes fludarabine Scheduled to receive a haploidentical graft Scheduled to receive postgrafting immunosuppression which includes oral mycophenolate mofetil (MMF) or entericcoated mycophenolic acid Age &gt;18 years at the time of enrollment Diagnosed with an immunodeficiency disorder, including HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>hematopoietic stem cell transplantation</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>fludarabine</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>mycophenolic acid</keyword>
	<keyword>biomarkers</keyword>
</DOC>